Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00997984

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder Clinical Trial

Official title:
A Phase 3, Double-blind, Randomized, Multicenter, Placebo-controlled, Dose Optimization Study Evaluating the Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children Aged 6-12 With a Diagnosis of Attention-Deficit/Hyperactivity Disorder

Clinical Trial Summary

The primary purpose is to assess the efficacy of once daily dosing with optimized SPD503 (1, 2, 3 and 4mg/day), dosed either in the morning or evening, compared to placebo, in children with ADHD as measured by change from baseline score at endpoint on the ADHD-RS-IV.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-Deficit/Hyperactivity Disorder
  • Hyperkinesis
Clinical Trial Details
NCT number NCT00997984
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date November 17, 2009
Completion date October 9, 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT02251743 - Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD N/A
Completed NCT02226445 - Treatment Drop-out and Missed Appointments Among Adults With ADHD N/A
Completed NCT01342445 - Effects of LDX on Functioning of College Students With ADHD Phase 4
Completed NCT00528697 - A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Not yet recruiting NCT00391495 - Inflammation in Children With Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT00494819 - Validity of ADHD Subtypes Using Neuropsychological Measure N/A
Completed NCT02217371 - Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity N/A
Completed NCT01081132 - Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl Phase 3
Completed NCT06064942 - Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00391729 - A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT00191048 - Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Phase 4
Terminated NCT00554385 - A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Not yet recruiting NCT05568446 - Social VR Based Intervention on Enhancing Social Interaction Skills in Children With AD/HD N/A
Completed NCT02096952 - Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD Phase 4
Recruiting NCT02623114 - Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers Phase 4
Completed NCT01351246 - Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) N/A
Completed NCT00686933 - Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 2
Completed NCT00491647 - Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder N/A
Completed NCT01081145 - Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) Phase 3
Recruiting NCT06185985 - Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms Phase 4